Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02352103 · ClinicalTrials.gov registry record · Phase 3

Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery

A Phase 3 study, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 3
Development phase
120
Enrollment target

NCT02352103: Completed Phase 3 study, sponsored by Henry Ford Health System.

NCT02352103 is a Phase 3 study that has completed, run by Henry Ford Health System. The registered enrollment target is 120 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02352103, a Phase 3 study, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 3
Development phase
120 participants
Enrollment target

Study Summary

To assess and compare the short-term post-operative continence recovery rate in two cohorts of men undergoing Robot Assisted Radical Prostatectomy (RARP), each randomized to undergo RARP with Vattikuti Institute technique or Retzius sparing technique.

Primary Outcome

24-hour pad weights

Interventions

  • PROCEDURE Retzius sparing radical prostatectomy
  • PROCEDURE Vattikuti Urology Institute radical prostatectomy
  • DEVICE da Vinci Surgical System

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2015-01
Est. Completion 2018-05
Phase Phase 3
Henry Ford Health System

234 total trials

What the finished NCT02352103 record still lists

NCT02352103 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 3 interventions - of which Retzius sparing radical prostatectomy is the first listed.

NCT02352103 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02352103 about?

NCT02352103 is a clinical study titled "Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery". To assess and compare the short-term post-operative continence recovery rate in two cohorts of men undergoing Robot Assisted Radical Prostatectomy (RARP), each randomized to undergo RARP with Vattikuti Institute technique or Retzius sparing technique.

What is the current status of trial NCT02352103?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2015-01. Estimated completion is 2018-05.

What interventions are being tested in trial NCT02352103?

The interventions under investigation include: Retzius sparing radical prostatectomy (PROCEDURE), Vattikuti Urology Institute radical prostatectomy (PROCEDURE), da Vinci Surgical System (DEVICE).

Who is sponsoring clinical trial NCT02352103?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02352103's enrollment target sits among peer trials

120 1619th of 2000 higher than 361 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02352103, the US trial registry maintained by the National Library of Medicine. NCT02352103 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.